Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | IBI354 |
Synonyms | |
Therapy Description |
IBI354 is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting monoclonal antibody linked to a camptothecin derivative, which potentially induces cell cycle arrest and apoptosis in Erbb2 (Her2)-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IBI354 | IBI-354|IBI 354 | HER2 (ERBB2) Antibody-Drug Conjugate 29 | IBI354 is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting monoclonal antibody linked to a camptothecin derivative, which potentially induces cell cycle arrest and apoptosis in Erbb2 (Her2)-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05636215 | Phase Ib/II | IBI354 | A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |